Efdamrofusp alfa
Based on 1 publication(s) in Google Scholar
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.
For research use only. We do not sell to patients.
- Purity: 99.89%
- CAS No.: 2375661-82-6
- Molecular Weight:140.4 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Efdamrofusp alfa
MoreAll VEGFR Isoforms
More
Biological Activity
Efdamrofusp alfa (0.135 mg/mL; 0, 6, 12, or 24 h) suppresses endothelial cell migration and tube formation[1].
Efdamrofusp alfa (0-1000 μg/mL) inhibits complement activation in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human primary umbilical vein endothelial cell (HUVEC)
-
Concentration:0.135 mg/mL
-
Incubation Time:0, 6, 12, or 24 h
-
Result:Showed a 20.91% reduction in migration.
Efdamrofusp alfa (1.35 mg; single intravitreal injection) shows favorable safety profiles and exhibited antiangiogenetic efficacy in a nonhuman primate laser-induced CNV model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice[1]
-
Dosage:13.5 μg; 13.0 μg
-
Administration:3 days; 7days
-
Result:Significantly reduced C3d deposition.
Reduced vascular leakage at 7 days after laser-induced injury.
Significantly suppressed CNV formation 7 days after laser-induced injury.
Reduced the concentrations of vitreous VEGF-A.
-
Animal Model:Rhesus monkeys[1]
-
Dosage:1.35 mg
-
Administration:Single intravitreal injection
-
Result:Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor)domain 2 fragment (14-204)-KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309)domain 3 fragment (206-308)-IGHG1 Fc (Fragment constant (205-431))-CR1 (complement receptor type 1, C3b/C4b receptor, C3BR, Knops blood group, KN, CD35)fragment (1-192)
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 2375661-82-6
-
Appearance Liquid
-
Molecular Weight 140.4 kDa
-
Color Colorless to light yellow
-
SMILES
[Efdamrofusp alfa]
-
Synonyms
IBI302
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)